亚宝药业
(600351)
| 流通市值：47.47亿 | | | 总市值：47.47亿 |
| 流通股本：6.92亿 | | | 总股本：6.92亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,708,712,223.13 | 1,139,408,464.81 | 614,533,394.31 | 2,686,037,568.67 |
| 营业收入 | 1,708,712,223.13 | 1,139,408,464.81 | 614,533,394.31 | 2,686,037,568.67 |
| 二、营业总成本 | 1,422,105,604.68 | 944,321,678.49 | 490,742,317.93 | 2,391,542,009.25 |
| 营业成本 | 817,879,312.83 | 540,585,784.67 | 289,256,463.32 | 1,297,853,138.07 |
| 税金及附加 | 26,599,855.66 | 17,290,947.31 | 8,831,932.81 | 34,045,339.09 |
| 销售费用 | 327,463,027.22 | 222,145,153.68 | 111,914,490.55 | 661,866,911.31 |
| 管理费用 | 180,385,376.52 | 116,732,896.12 | 59,383,276.34 | 259,067,167.24 |
| 研发费用 | 72,291,467.66 | 48,536,984.41 | 21,567,036.65 | 139,523,419.89 |
| 财务费用 | -2,513,435.21 | -970,087.7 | -210,881.74 | -813,966.35 |
| 其中:利息费用 | 1,097,123.49 | 1,205,793.04 | 644,477.45 | 5,347,631.23 |
| 其中:利息收入 | 3,872,574.2 | 2,347,848.85 | 892,131.73 | 6,448,673.81 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,085,508.33 | 419,744.99 | 452,808.9 | -2,847,479.62 |
| 加:投资收益 | 1,557,235.64 | 992,783.8 | 603,719.9 | -188,368.93 |
| 资产处置收益 | 70,086.07 | 50,194.26 | 26,605.32 | 347,086.9 |
| 资产减值损失(新) | -66,395,069.1 | -10,010,853.29 | -3,095,784.05 | -42,162,919.81 |
| 信用减值损失(新) | 10,487,798.34 | 7,487,536.47 | -2,783,962.95 | 4,875,175.46 |
| 其他收益 | 19,846,672.94 | 17,991,574.96 | 9,327,516.84 | 45,434,066.6 |
| 四、营业利润 | 253,258,850.67 | 212,017,767.51 | 128,321,980.34 | 299,953,120.02 |
| 加:营业外收入 | 3,289,402.95 | 1,141,454.1 | 616,576.88 | 1,634,646.67 |
| 减:营业外支出 | 3,184,289.28 | 729,081.77 | 633,172.16 | 9,479,638.95 |
| 五、利润总额 | 253,363,964.34 | 212,430,139.84 | 128,305,385.06 | 292,108,127.74 |
| 减:所得税费用 | 54,872,495.17 | 37,241,723.11 | 22,236,917.2 | 68,192,627.05 |
| 六、净利润 | 198,491,469.17 | 175,188,416.73 | 106,068,467.86 | 223,915,500.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 198,491,469.17 | 175,188,416.73 | 106,068,467.86 | 223,915,500.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 215,094,293.85 | 174,397,240.67 | 107,269,233.54 | 242,688,462.41 |
| 少数股东损益 | -16,602,824.68 | 791,176.06 | -1,200,765.68 | -18,772,961.72 |
| 扣除非经常损益后的净利润 | 197,453,009.3 | 159,681,557.75 | 100,877,438.17 | 215,457,408.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.31 | 0.25 | 0.15 | 0.34 |
| 八、其他综合收益 | - | - | - | -1,288,990.13 |
| 归属于母公司股东的其他综合收益 | - | - | - | -1,288,990.13 |
| 九、综合收益总额 | 198,491,469.17 | 175,188,416.73 | 106,068,467.86 | 222,626,510.56 |
| 归属于母公司股东的综合收益总额 | 215,094,293.85 | 174,397,240.67 | 107,269,233.54 | 241,399,472.28 |
| 归属于少数股东的综合收益总额 | -16,602,824.68 | 791,176.06 | -1,200,765.68 | -18,772,961.72 |
| 公告日期 | 2025-10-25 | 2025-08-16 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |